Supply Chain Simulator targets pharmaceutical industry.
Share:
Press Release Summary:
Helping to avoid costly errors, tcVisualize(TM) 2.0 lets pharmaceutical companies model, visualize, and simulate complex clinical supply scenarios. Users can plan and play out unlimited scenarios, vary relevant study parameters, and zoom between global picture and individual site view. With live study tracking and reporting, and ability to replay in-progress studies or run them forward with existing or altered parameters, companies can track supplies at all times.
Original Press Release:
Tourtellotte Solutions Unveils Powerful Supply Chain Simulator for the Pharmaceutical Industry
tcVisualize(TM) 2.0 will Safeguard Patient Safety and Save Pharmas Millions by Modeling and Predicting Clinical Trial Supply Chains
WAYLAND, Mass., Oct. 19 // -- Tourtellotte Solutions, a global leader in custom and packaged supply chain software for the pharmaceutical, retail, and consumer goods markets, has unveiled a new, significantly enhanced "2.0" release of its groundbreaking tcVisualize(TM) application, the most advanced clinical supply modeling tool available to the pharmaceutical industry today. tcVisualize lets pharmaceutical companies model, visualize, and simulate complex clinical supply scenarios -- and avoid costly errors. By implementing this clinical trial simulator, pharmaceuticals can save millions of dollars by reducing waste and trial delays, safeguard patient health by eliminating stock-outs, and ultimately get drugs to the approval stage faster.
"We designed tcVisualize to fill a void in the clinical supply process that has become increasingly painful for the pharmaceutical industry," said Ed Tourtellotte, president and CEO of Tourtellotte Solutions. "Until tcVisualize, no product existed that could graphically model and forecast all of the complexities of the clinical supply chain."
The new, more powerful tcVisualize expands the user's ability to plan and play out unlimited supply chain scenarios, vary all relevant study parameters, and zoom between the global picture and individual site view. New, easily- understandable live study tracking and reporting, as well as the capability to replay in-progress studies, or run them forward with existing or altered parameters, enables pharmaceuticals to know the location of supplies today, tomorrow, or in a week.
tcVisualize's capabilities address high-stakes issues for pharmaceuticals: baseline and overage supply requirements, lot expiration and resupply considerations, aggregate costs of drugs and shipments, and ultimately, the viability of any clinical supply plan either prior to or during a study. The addition of live data to the 2.0 release adds day-by-day replay and analysis, real-time study tracking, and current and future supply chain disposition. With these insights, clinical trials can now be less time consuming, less wasteful, and safer for patients.
For more information on Tourtellotte Solutions and tcVisualize 2.0(TM), go to http://www.tourtellottesolutions.com/.
About Tourtellotte Solutions
Tourtellotte Solutions is a global leader in custom and packaged supply-chain software for the pharmaceutical, retail, and consumer goods markets. Tourtellotte Solutions' RockBlocks(R) product -- the most widely-adopted sourcing software on the planet for retail, consumer goods, branded apparel, and footwear manufacturers -- processes billions of dollars of transactions each year in over 50 countries. RockBlocks users include Staples, Target, Radio Shack, JC Penney, The Home Depot, Saks, Federated Department Stores, Lenox, Timberland, Payless, Stride Rite, and Sara Lee. Tourtellotte Solutions' tcVisualize(TM), a groundbreaking clinical supply chain modeling and forecasting application for the pharmaceutical industry, is used by several of the largest pharmaceuticals. Tourtellotte Solutions is a privately-held company headquartered in Wayland, Massachusetts. For more information on Tourtellotte Solutions, please call Eileen Prose at 866.653.2770 x144, or visit http://www.tourtellottesolutions.com/.
